Table 2.
Second-line therapy used.
| Overall (N = 839) | |
|---|---|
| AI | 23 (2.7%) |
| CDK4/6i | 4 (0.5%) |
| CDK4/6i + AI | 97 (11.6%) |
| CDK4/6i + F | 160 (19.1%) |
| CDK4/6i + F + AI | 35 (4.2%) |
| CDK4/6i + F + T | 3 (0.4%) |
| CDK4/6i + T | 3 (0.4%) |
| Chemotherapy | 249 (29.7%) |
| F | 70 (8.3%) |
| F + AI | 14 (1.7%) |
| Everolimus | 99 (11.7%) |
| PARP Inhibitor | 4 (0.5%) |
| Alpelisib | 16 (1.9%) |
| T | 11 (1.3%) |
| Clinical Trial | 51 (6.1%) |
Abbrevistions: AI, aromatase inhibitor; CDK4/6i, cyclin-dependent kinases 4/6 inhibitor; F, fulvestrant; T, tamoxifen; PARP, poly(ADP ribose) polymerase.